When the world frets over drug shortages, Gland casually adds “140 million cartridge capacity” like it’s restocking needles at a clinic. As Wall Street analysts sip caffeine to stay awake through U.S. FDA jargon, Gland Pharma drops GLP-1 mic moments and margin miracles. Somewhere in Hyderabad, a CFO smiles—because 37% EBITDA doesn’t happen by accident, it happens by automation and divine process control. As the Bhagavad Gita says, “Yoga is skill in action” — clearly, Gland’s got that sorted.
Stick around — the dosage gets stronger later.
At a Glance
- Revenue up 6% – Management calls it “steady”; analysts call it “pharma caffeine.”
- EBITDA up 6% – Flat in shape, sharp in intent — powered by Cenexi’s French revival.
- Margins at 21% – Even the supply chain behaved, for once.
- PAT ₹1,837 Cr – Playing it cool at 12% margin.
- R&D at 5.8% of sales – Because complex injectables need complex cheques.
- Cash ₹3,100 Cr+ – Enough buffer to outlast regulatory heartburn.
Management’s Key Commentary
Srinivas Sadu: “Q2FY26 was another strong quarter; H2 will be stronger.”
(Translation: The party hasn’t peaked — yet.)
Sadu: “U.S. tariff relief aligns with our strategy.”
(Translation: Thank you, Uncle Sam, for not taxing our vials of hope.)
Giri:
